Barclays lowered the firm’s price target on Pacira to $38 from $40 and keeps an Overweight rating on the shares post the Q1 report. The analyst says the company’s Exparel revenue of $132M was in-line with consensus.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
- Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
- PCRX Earnings this Week: How Will it Perform?
- Pacira granted RMAT designation for PCRX-201
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
